The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform
Jianguo Zhao - One of the best experts on this subject based on the ideXlab platform.
-
Glucagonoma syndrome with severe erythematous rash: A rare case report.
Medicine, 2019Co-Authors: Zhenxia Wang, Fei Wang, Jianguo ZhaoAbstract:RATIONALE Glucagonoma is a rare neuroendocrine tumor of the pancreas. Glucagonoma syndrome is often misdiagnosed as other skin lesions by clinicians due to a typical clinical sign of necrolytic migratory erythema (NME) with severe erythematous rash. PATIENT CONCERNS A 48-year-old female patient was admitted to our department because she presented with unclear recurrent severe erythematous rash. The patient was diagnosed as skin disease. DIAGNOSES Histopathologic examination revealed a pancreatic Glucagonoma. Immnohistochemical staining of tumor tissue was positive for glucagon. INTERVENTIONS The distal pancreatectomy plus splenectomy was performed in 2017. OUTCOMES The skin lesions disappeared after surgery. She was followed up and showed no recurrence until now. LESSONS Clinicians should consider the diagnosis of Glucagonoma according to the typical initial symptoms. Early diagnosis is very important to provide a better prognosis. A multidisciplinary approach is effective in patients with unresectable metastatic tumors.
Hironobu Minami - One of the best experts on this subject based on the ideXlab platform.
-
Necrolytic Migratory Erythema Associated with Pancreatic Glucagonoma
Annals of Oncology, 2012Co-Authors: Shiro Kimbara, Y. Fujiwara, Masanori Toyoda, Naoko Chayahara, Y. Imanura, Naomi Kiyota, T. Shimada, Toru Mukohara, Hironobu MinamiAbstract:ABSTRACT Glucagonoma, a rare tumor derived from the a-cells of the pancreas, has an estimated incidence of approximately one in 20 million people per year. This glucagogenesis results in clinical manifestations including necrolytic migratory erythema (NME), cheilitis, diabetes mellitus, anemia, weight loss, among others. Of these, NME is a well-known paraneoplastic symptom observed in patients with Glucagonoma. However, NME is often missed at initial investigation, and the correct diagnosis of Glucagonoma tends to be delayed.We report a 46-year-old Japanese woman with Glucagonoma who presented with mucocutaneous manifestations 1 year before the diagnosis of the pancreatic neoplasm with multiple liver metastases. Contrast-enhanced dynamic CT of the abdomen revealed multiple tumors in the pancreatic tail and liver, which were enhanced during the early arterial phase and washed out in the delayed phase. Liver biopsy showed well-differentiated neuroendocrine tumor. These histopathologic features in skin biopsy were suggestive of NME. Serum glucagon concentration was 8,400 pg/ml (normal range 70-160 pg/ml). Based on these findings, the diagnosis of Glucagonoma with NME was confirmed. Because she had unresectable metastatic disease, she was treated with octreotide, a somatostatin analog. NME was dramatically improved within 2 weeks after initiation of octreotide. The rarity of Glucagonoma has hampered a closer understanding of its pathophysiological mechanisms, which together with its non-specific clinical manifestations means that diagnosis is often relatively late in the course of the disease. Though several novel agents such as octreotide, sunitinib and everolimus provide clinical benefits for patients with advanced Glucagonoma, complete resection still represents the only potentially curative treatment. Earlier recognition of NME, the characteristic skin lesion of Glucagonoma syndrome, will facilitate the correct diagnosis of this condition.
Shiro Kimbara - One of the best experts on this subject based on the ideXlab platform.
-
Rapid improvement of Glucagonoma-related necrolytic migratory erythema with octreotide.
Clinical journal of gastroenterology, 2014Co-Authors: Shiro Kimbara, Y. Fujiwara, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yoshinori Imamura, Atsushi Fukunaga, Masahiro Oka, Chikako NishigoriAbstract:Necrolytic migratory erythema (NME) is a classical paraneoplastic symptom observed in patients with pancreatic Glucagonoma. We report a 46-year-old Japanese woman with Glucagonoma who presented with mucocutaneous manifestations 1 year prior to the diagnosis of the pancreatic neoplasm with multiple liver metastases. She was treated with octreotide long-acting release, a somatostatin analog, which resulted in a dramatic improvement of NME within 2 weeks after the start of treatment. Increased awareness of NME may avoid unnecessary delay in the diagnosis of pancreatic Glucagonoma.
-
Necrolytic Migratory Erythema Associated with Pancreatic Glucagonoma
Annals of Oncology, 2012Co-Authors: Shiro Kimbara, Y. Fujiwara, Masanori Toyoda, Naoko Chayahara, Y. Imanura, Naomi Kiyota, T. Shimada, Toru Mukohara, Hironobu MinamiAbstract:ABSTRACT Glucagonoma, a rare tumor derived from the a-cells of the pancreas, has an estimated incidence of approximately one in 20 million people per year. This glucagogenesis results in clinical manifestations including necrolytic migratory erythema (NME), cheilitis, diabetes mellitus, anemia, weight loss, among others. Of these, NME is a well-known paraneoplastic symptom observed in patients with Glucagonoma. However, NME is often missed at initial investigation, and the correct diagnosis of Glucagonoma tends to be delayed.We report a 46-year-old Japanese woman with Glucagonoma who presented with mucocutaneous manifestations 1 year before the diagnosis of the pancreatic neoplasm with multiple liver metastases. Contrast-enhanced dynamic CT of the abdomen revealed multiple tumors in the pancreatic tail and liver, which were enhanced during the early arterial phase and washed out in the delayed phase. Liver biopsy showed well-differentiated neuroendocrine tumor. These histopathologic features in skin biopsy were suggestive of NME. Serum glucagon concentration was 8,400 pg/ml (normal range 70-160 pg/ml). Based on these findings, the diagnosis of Glucagonoma with NME was confirmed. Because she had unresectable metastatic disease, she was treated with octreotide, a somatostatin analog. NME was dramatically improved within 2 weeks after initiation of octreotide. The rarity of Glucagonoma has hampered a closer understanding of its pathophysiological mechanisms, which together with its non-specific clinical manifestations means that diagnosis is often relatively late in the course of the disease. Though several novel agents such as octreotide, sunitinib and everolimus provide clinical benefits for patients with advanced Glucagonoma, complete resection still represents the only potentially curative treatment. Earlier recognition of NME, the characteristic skin lesion of Glucagonoma syndrome, will facilitate the correct diagnosis of this condition.
Ramón Naranjo - One of the best experts on this subject based on the ideXlab platform.
-
Eritema necrolítico migratorio asociado a Glucagonoma
Actas dermo-sifiliograficas, 2005Co-Authors: Francisco Mendoza-guil, Isabel Hernández-jurado, Pilar Burkhardt, Juan Carlos Linares, Ramón NaranjoAbstract:Glucagonoma is a rare pancreatic tumor that is usually associated with a syndrome that includes diabetes, anemia, weight loss and skin lesions in the form of necrolytic migratory erythema. We present the case of a patient with malignant Glucagonoma treated with surgery and octreotide, which manifested with skin lesions. The discussion will review the physiopathology, other causes of necrolytic erythema, diagnosis and differential diagnosis and treatment.
Zhenxia Wang - One of the best experts on this subject based on the ideXlab platform.
-
Glucagonoma syndrome with severe erythematous rash: A rare case report.
Medicine, 2019Co-Authors: Zhenxia Wang, Fei Wang, Jianguo ZhaoAbstract:RATIONALE Glucagonoma is a rare neuroendocrine tumor of the pancreas. Glucagonoma syndrome is often misdiagnosed as other skin lesions by clinicians due to a typical clinical sign of necrolytic migratory erythema (NME) with severe erythematous rash. PATIENT CONCERNS A 48-year-old female patient was admitted to our department because she presented with unclear recurrent severe erythematous rash. The patient was diagnosed as skin disease. DIAGNOSES Histopathologic examination revealed a pancreatic Glucagonoma. Immnohistochemical staining of tumor tissue was positive for glucagon. INTERVENTIONS The distal pancreatectomy plus splenectomy was performed in 2017. OUTCOMES The skin lesions disappeared after surgery. She was followed up and showed no recurrence until now. LESSONS Clinicians should consider the diagnosis of Glucagonoma according to the typical initial symptoms. Early diagnosis is very important to provide a better prognosis. A multidisciplinary approach is effective in patients with unresectable metastatic tumors.